Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
about
VICKZ proteins: a multi-talented family of regulatory RNA-binding proteinsThe Keap1-Nrf2 system in cancers: stress response and anabolic metabolismAssociation of p62/SQSTM1 excess and oral carcinogenesis.Linking the ovarian cancer transcriptome and immunomeIdentification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer.A 7 gene expression score predicts for radiation response in cancer cervixHumoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype.Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.Autoimmune Response to IGF2 mRNA-Binding Protein 2 (IMP2/p62) in Breast Cancer.Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease researchAutoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.Tumor-associated antigen arrays for the serological diagnosis of cancer.p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer.Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma.Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?Autoantibodies to tumor-associated antigens: reporters from the immune system.Alteration of p62/SQSTM1 Expression Is Uncommon in Gastrointestinal and Prostate Cancer Tissues.Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.Serum autoantibodies as biomarkers for early cancer detection.Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors.Sequestosome 1/p62: across diseases.Broad spectrum of hepatocyte inclusions in humans, animals, and experimental models.Impaired autophagy response in human hepatocellular carcinoma.The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis.IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype.P62/Ubiquitin IHC Expression Correlated with Clinicopathologic Parameters and Outcome in Gastrointestinal Carcinomasp62 Expression in primary carcinomas of the digestive system.The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC?Humoral autoimmune response to IGF2 mRNA-binding protein (IMP2/p62) and its tissue-specific expression in colon cancer.IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer.IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling.Dr Eng M. Tan: a tribute to an enduring legacy in autoimmunity.Disease- and cell-specific expression of GP73 in human liver disease.
P2860
Q28298447-46D5E76E-1DB7-4895-89D1-B31F5DA711D0Q28392347-8FF6DBD7-77AC-4136-B760-14EA144E4C94Q30448830-C2F2393D-F4C9-4585-9189-59725C413229Q33313203-46639B4B-602E-40A4-9F22-CC8FBFDBFA4FQ33432974-A52D0DD1-6949-4844-9437-8D9AD7C3B548Q33510812-F0207ABE-0FAB-4FE3-9731-34134927C615Q33608271-EC5B9DB9-437C-469C-9ED8-77BD7D19FD85Q34138916-9EAD316A-39AB-44E6-8724-2236D4E1DDD3Q34750585-D14E95B8-2CAE-4743-B551-33D85192B570Q34810309-F7FC426D-2168-4C95-AE40-D1246157477AQ35059164-78E0BC50-3D06-4F7A-A13B-65C73FCFC1D4Q35583352-F1DFD9BE-47B6-4FE7-B6B0-C6E06C549B76Q35607101-8A0C927E-9EE8-4FFF-854B-F41BB771400AQ35987358-6450736C-D907-4754-8FA0-4D0B2A301977Q36129673-CFEC1BAF-EC0B-4E1E-957E-49003E98D84FQ36169087-65B41003-CB9B-4876-8FED-DD1146D37286Q36491988-79931C78-6DC3-4029-9E7B-086DFE22E82EQ36544933-476EECCD-0589-4499-AAEC-D285B5996D0CQ36731844-9EA96A06-308D-4FD9-8845-246961554BCCQ37002361-FD3215C2-8D22-4A7C-8A88-4ED677D41AB9Q37118192-719E07B8-1694-47F3-9C0E-3B29FB9F7A92Q37196504-31E49899-307A-4011-9263-6F58B63C6674Q37213540-8C24E86C-55EF-4EC3-8CBD-BEF61738BD11Q37252915-F6900076-E091-48A6-93F2-DEEA3C37E7F6Q37536632-0560456D-3E95-4AE8-ABB2-D45B30293AEBQ37622471-38E87C75-8044-4F11-82C6-ADCDE3605B85Q37724875-79CACAD8-B23E-48F3-8071-A3FDE317284FQ37980487-6161E579-8EB9-4DF6-A580-3AA070BB84DCQ38165139-A2D5A343-FD68-44EF-BDAC-E7EB6E308BE6Q38393661-409E990C-CE9A-48EE-A3A5-FE08CB478334Q39896001-0ED5A816-D02A-4AC7-B027-7266E07B82C5Q40478066-24F324E4-F082-4A13-AD80-F9979323E1AFQ41077235-0D2866C7-F0F4-4252-93A3-51B409DE7EDBQ42113747-447C3258-FAB5-483C-BA14-E5FDC1D949ABQ42338073-C01AE12D-A6C8-4FCD-ABB5-37972A11EC5BQ43818115-E00FB978-699C-40F7-8423-D3BB4A7DDE0FQ46256483-8AB91B6F-D7F7-4AB0-9D25-6F233C805AFCQ46873887-FD4F86F5-CC97-419D-8219-D5423B0113FAQ47187009-7E28E653-2958-4DDA-9BD6-8434DD9C70E2Q47387960-68B1DCB3-7EFA-485F-A079-4C84EE2E0E82
P2860
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
@ast
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
@en
type
label
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
@ast
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
@en
prefLabel
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
@ast
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
@en
P2093
P2860
P1476
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.
@en
P2093
F C Nielsen
J Christiansen
R M Nakamura
P2860
P304
P356
10.1016/S0002-9440(10)61770-1
P407
P577
2001-09-01T00:00:00Z